|Bid||63.89 x 1400|
|Ask||63.88 x 1400|
|Day's range||63.52 - 64.05|
|52-week range||46.47 - 64.82|
|Beta (5Y monthly)||0.53|
|PE ratio (TTM)||25.93|
|Forward dividend & yield||1.57 (2.48%)|
|Ex-dividend date||26 Mar 2020|
|1y target est||65.72|
Oscar Health is offering prescription drugs at rock-bottom prices, following the lead of other health care players responding to the public’s demand for lower costs.
It's been a good week for Novo Nordisk A/S (CPH:NOVO B) shareholders, because the company has just released its latest...
Britain's brightest and best drug researchers are packing their bags as clinical trials start to dwindle, leaving a nation renowned as a global leader in pharmaceutical development to face a future in the slow lane. This is a worst-case scenario outlined by some scientists and industry experts in the wake of Brexit, which they say could deprive the country of its role as Europe's leader in early-stage drug research, designing and hosting pan-EU trials. Pamela Kearns, professor of paediatric oncology at the University of Birmingham, worries that over time Britain will in particular lose out in the field of medicines that treat rare diseases and childhood cancers, where trials often need to collaborate and recruit across Europe to find enough patients.
Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.
Novo Nordisk's new diabetes pill, Rybelsus, will be covered by Express Scripts Holding Co, one of the largest U.S. pharmacy benefit managers, the Danish drugmaker said on Friday. Pharmacy benefit managers act as middlemen in the drug supply chain, and negotiate discounts on drugs on behalf of health insurers. Depending on the discounts drugmakers are willing to provide, pharmacy benefits managers make decisions about which drugs to include in coverage plans.
Is Novo Nordisk A/S (CPH:NOVO B) a good dividend stock? How can we tell? Dividend paying companies with growing...
Gilead's (GILD) mid-stage study on combination and monotherapy investigational treatments for advanced fibrosis due to NASH fails to meet the primary endpoint.
Novo Nordisk (NVO) inks deal with Dicerna Pharmaceuticals to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases.
The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.
Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.